Based on the biodistribution profile, including limited uptake in adipose tissue, and the mild toxicity profile of (177Lu)-PSMA, a fixed dose seems appropriate for treatment of patients with obesity. This evidence concerns the gene FOLH1 and obesity due to melanocortin 4 receptor deficiency.